Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Neurology  |  Rheumatology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Scleroderma Clinical Trials

A listing of Scleroderma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (27) clinical trials

Systemic Sclerosis (SSc) is a devastating and often life threatening illness predominantly affecting women characterized by autoimmunity, widespread microvascular disease, and fibrosis, especially of the skin, gastrointestinal tract, and lung. Multiple studies have shown evidence of platelet activation in SSc. Chronic intermittent vasospasm in the microvasculature combined with platelet aggregation ...

Phase N/A

Participation in this study would last approximately 96 weeks and would include approximately 12 visits to our office. Compensation may be provided for time and travel

Phase

The study will determine how well the treatment with the study drug called nintedanib can demonstrate a slowing in the rate of lung scarring (or fibrosis) and how well the study treatment has an effect on the skin thickening.

Phase

Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis

PROTOCOL OUTLINE: Patients undergo punch skin biopsy obtained from the upper arm or back. Studies of fibrillin-1 synthesis and cellular processing, and FBN1 mutational analysis, linkage analysis, and genetic mapping are performed on the tissue samples. Patients from all major US ethnic groups (Caucasian, Hispanic, African Americans) will be recruited ...

Phase N/A

Study of Families With Twins or Siblings Discordant for Rheumatic Disorders

Most autoimmune diseases are thought to develop as a result of chronic immune activation and dysregulation after selected environmental exposures in genetically susceptible individuals. Current evidence suggests that the adult and juvenile forms of systemic rheumatic disorders -- defined here as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis ...

Phase N/A

CSL Behring Sclero XIII

This is a phase II, double-blind, randomized, placebo-controlled study to investigate pharmacokinetics (PK), safety and efficacy of intravenous factor XIII treatment in patients with systemic sclerosis. Scleroderma (Systemic sclerosis) is a multisystem rheumatic disease that is characterised by progressive vascular damage e.g Raynaud's phenomenon and digital ulcers and organ fibrosis ...

Phase

Scleroderma Registry

Scleroderma refers to a group of diseases that involve the abnormal growth of connective tissue, which supports the skin and internal organs. Scleroderma can affect the skin, making it hard and tight; it can also damage the blood vessels and internal organs such as the heart, lungs, and kidneys. Estimates ...

Phase N/A

High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early Rapidly Progressive Diffuse Systemic Sclerosis

- Systemic sclerosis (scleroderma; SSc) is a rare, disfiguring systemic disorder characterized by fibrosis of the skin and visceral organs that alters every aspect of an individual life - Although some features of scleroderma phenotype are well established and represent the hallmarks of the disease, the primary cause is not ...

Phase

Non-Invasive Diagnostic and Functional Evaluation of Cardiac Involvement in Patients With Systemic Sclerosis

Elevated serum brain natriuretic peptide (BNP) levels released from myocytes of ventricles upon stretch have been found in patients with isolated right ventricular (RV) pressure overload. However, limited data suggest that serum BNP may be elevated in patients with systemic sclerosis (SSc), especially with RV dysfunction. The aim of this ...

Phase N/A

Platelet Gel in Systemic Sclerosis

- Systemic sclerosis (scleroderma; SSc) is a connective tissue disease characterized by a progressive fibrosis of the skin and visceral organs. - A diffuse cutaneous microvascular damage occurs in 30-50% of patients, often leading to digital ulcers development, responsible for pain, functional disability, disfiguring scars, digital bony reabsorption, infection and ...

Phase